Cambium Bio Ltd

CMB

Company Profile

  • Business description

    Cambium Bio Ltd is a clinical-stage regenerative medicine company in Australia. It focuses on the development of biologics for ophthalmology and tissue repair applications. Its technology platform is based on human platelet lysate, which is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. The company's product candidate, Elate Ocular, is being developed to address unmet medical needs in the treatment of dry eye disease. In addition, its stem cell platform, Progenza, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications.

  • Contact

    Unit 2.06, 31 Lexington Drive
    Bella VistaNSW2153
    AUS

    T: +61 1300995098

    https://www.cambium.bio

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2026

    Employees

Stocks News & Analysis

stocks

Will China strong arm BHP into lower iron ore prices?

Allegations that the Chinese government told steel mills to stop buying from BHP shake markets.
stocks

Chart of the Week: Where Morningstar sees attractive dividend yields in 26/27

Charts from the Australian Dividend Outlook show the sectors where they are abundant.
stocks

2 picks in an undervalued ASX sector

Investors may be too pessimistic about this industry.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,287.109.40-0.10%
CAC 408,060.1385.281.07%
DAX 4024,597.13211.350.87%
Dow JONES (US)46,601.781.20-0.00%
FTSE 1009,548.8765.290.69%
HKSE26,829.46128.31-0.48%
NASDAQ23,043.38255.021.12%
Nikkei 22547,734.99215.89-0.45%
NZX 50 Index13,611.0942.610.31%
S&P 5006,753.7239.130.58%
S&P/ASX 2008,983.6011.40-0.13%
SSE Composite Index3,882.7820.250.52%

Market Movers